CGS 21680 exerts marked antidystonic effects in a genetic model of paroxysmal dyskinesia

Author： Richter A.   Hamann M.   Bartling C.  

Publisher： Elsevier

ISSN： 0014-2999

Source： European Journal of Pharmacology, Vol.404, Iss.3, 2000-09, pp. : 299-302

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia

By Richter A.   Loscher W.  

European Journal of Pharmacology, Vol. 454, Iss. 2, 2002-11 ,pp. : 145-151

Elsevier

Access to resources Recommend Favorite

Effects of adenosine A 2A receptor agonist, CGS 21680, on blood pressure, cardiac index and arterial conductance in anaesthetized rats

By Nekooeian A.A.   Tabrizchi R.  

European Journal of Pharmacology, Vol. 307, Iss. 2, 1996-06 ,pp. : 163-169

Elsevier

Access to resources Recommend Favorite

Effects of CGS 21680, a selective adenosine A 2A receptor agonist, on allergic airways inflammation in the rat

By Fozard J.R.   Ellis K.M.   Villela Dantas M.F.   Tigani B.   Mazzoni L.  

European Journal of Pharmacology, Vol. 438, Iss. 3, 2002-03 ,pp. : 183-188

Elsevier

Access to resources Recommend Favorite

The kynurenine 3-hydroxylase inhibitor Ro 61-8048 improves dystonia in a genetic model of paroxysmal dyskinesia

By Richter A.   Hamann M.  

European Journal of Pharmacology, Vol. 478, Iss. 1, 2003-09 ,pp. : 47-52

Elsevier

Access to resources Recommend Favorite

Piracetam and levetiracetam, two pyrrolidone derivatives, exert antidystonic activity in a hamster model of paroxysmal dystonia

By Loscher W.   Richter A.  

European Journal of Pharmacology, Vol. 391, Iss. 3, 2000-03 ,pp. : 251-254

Elsevier

Access to resources Recommend Favorite